

CITATION REPORT

List of articles citing

Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability

DOI: 10.1016/s0149-2918(04)90066-5
Clinical Therapeutics, 2004, 26, 649-66.

Source: <https://exaly.com/paper-pdf/37601566/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
309	Use of olanzapine in the treatment of bipolar I disorder. 2004 , 4, 759-67		8
308	From clinical research to clinical practice: a 4-year review of ziprasidone. 2005 , 10, 1-20		22
307	Aripiprazole in the treatment of delirium. 2005 , 35, 429-33		20
306	Modalit� d'utilisation des neuroleptiques. 2005 , 2, 1-27		1
305	The art of prescribing. Principles of switching novel antipsychotic medications. 2005 , 41, 45-7		5
304	Partial agonists in schizophrenia. 2005 , 186, 354		3
303	A Candidate Pathway Strategy for Integration of Pharmacogenomic Components of Variability in Antipsychotic Treatment Outcomes: A Focus on Aripiprazole. 2005 , 3, 305-317		3
302	Omega-3 fatty acids and neuropsychiatric disorders. 2005 , 45, 1-28		181
301	Aripiprazole: pharmacology, efficacy, safety and tolerability. 2005 , 5, 297-307		35
300	Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. 2005 , 20, 15-27		122
299	Psychotropic medication use at a private eating disorders treatment facility: A retrospective chart review and descriptive data analysis. 2005 , 66, 572-88		4
298	First-episode schizophrenia: a focus on pharmacological treatment and safety considerations. 2005 , 65, 1113-38		35
297	Modalit� d'utilisation des neuroleptiques. 2005 , 2, 300-339		4
296	A pilot study of aripiprazole in children and adolescents with Tourette's disorder. 2006 , 16, 505-6		40
295	A case of Aripiprazole and extra pyramidal side effects. 2006 , 20, 592-3		10
294	Use of aripiprazole for psychosis and agitation in dementia. 2006 , 18, 335-40		4
293	ADHD and schizophrenia phenomenology: visual scanpaths to emotional faces as a potential psychophysiological marker?. 2006 , 30, 651-65		60

292	LCBSIMS for Rapid and Sensitive Determination of Aripiprazole in Human Plasma. 2006 , 64, 387-391	17
291	A case series of patients with Tourette's syndrome in the United Kingdom treated with aripiprazole. 2006 , 21, 447-53	53
290	Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. 2006 , 163, 833-8	158
289	Aripiprazole and delirium. 2006 , 18, 267-9	21
288	Reversibility of antipsychotic treatment-related diabetes in patients with schizophrenia: a case series of switching to aripiprazole. 2006 , 29, 2329-30	20
287	Intravenous quetiapine-cocaine use ("Q-ball"). 2007 , 164, 173-4	32
286	N-dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1-aryl-piperazines formed. 2007 , 8, 612-22	46
285	Adjunctive aripiprazole in bipolar I depression. 2007 , 41, 35-40	22
284	A case series: evaluation of the metabolic safety of aripiprazole. 2007 , 33, 823-30	52
283	Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disabilities. 2007 , 64, 827-9	3
282	Dopamine and Glutamate Hypotheses of Schizophrenia. 2007 ,	
281	Aripiprazole: effectiveness and safety under naturalistic conditions. 2007 , 15, 569-75	14
280	Effectiveness and tolerability of aripiprazole in child and adolescent inpatients: a retrospective evaluation. 2007 , 22, 101-5	15
279	Hyperglycemia in a 7-year-old child treated with aripiprazole. 2007 , 164, 173	40
278	Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma. 2007 , 13, 120-4	12
277	Manic episode during treatment with aripiprazole. 2007 , 164, 172-3	13
276	Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. 2007 , 27, 639-61	120
275	Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study. 2007 , 31, 373-7	32

274	Aripiprazole in delusional parasitosis: Case report. 2007 , 31, 784-6	22
273	Reaching for wellness in schizophrenia. 2007 , 30, 453-79	12
272	Aripiprazole: pharmacology and evidence in bipolar disorder. 2007 , 8, 1001-9	25
271	Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. 2007 , 50, 5103-8	16
270	Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. 2007 , 15, 918-31	103
269	Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. 2007 , 46, 359-88	183
268	Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse. 2007 , 61, 582-90	76
267	Two new phenylpiperazines with atypical antipsychotic potential. 2007 , 17, 5749-53	16
266	Detection and quantification of aripiprazole and its metabolite, dehydroaripiprazole, by gas chromatography-mass spectrometry in blood samples of psychiatric patients. 2007 , 856, 57-61	27
265	Approaches to the development of medications for the treatment of methamphetamine dependence. 2007 , 102 Suppl 1, 96-106	100
264	In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. 2007 , 191, 745-58	82
263	Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice. 2008 , 199, 37-46	40
262	Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain. 2008 , 86, 457-64	25
261	Effects of aripiprazole on subjective and physiological responses to alcohol. 2008 , 32, 573-9	27
260	Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control. 2008 , 32, 1954-61	29
259	Aripiprazole-induced acneiform eruption. 2008 , 30, 479-81	8
258	Adjunctive aripiprazole for bupropion-resistant major depression. 2008 , 42, 1124-9	7
257	Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. 2008 , 105, 10978-83	185

256	Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. 2008 , 22, 367-88	56
255	Emergence of electric shock-like sensations on escitalopram discontinuation. 2008 , 28, 359-60	3
254	Topiramate treatment of women with borderline personality disorder, part II: an open 18-month follow-up. 2008 , 28, 355-7	13
253	Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. 2008 , 9, 410-8	154
252	Comments on "Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II Study)" by Dr Thase and colleagues. 2008 , 28, 367; author reply 368	
251	Comments on "Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II Study)" by Dr Thase and colleagues. 2008 , 28, 367-8; author reply 368	1
250	Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study. 2008 , 28, 349-52	34
249	Acute pregabalin reversal of citalopram-induced sexual dysfunction in generalized anxiety disorder. 2008 , 28, 362-63	3
248	Aripiprazole treatment causes extrapyramidal side effects but not prolactin elevation: a disconnect of the striatal D2 occupancy story: case report. 2008 , 28, 353-4	2
247	A case of hyperammonemic encephalopathy after 11 years of valproate therapy. 2008 , 28, 361-2	12
246	Risperidone treatment of borderline personality disorder assessed by a borderline personality disorder-specific outcome measure: a pilot study. 2008 , 28, 345-7	9
245	A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. 2008 , 28, 5-12	76
244	Reply to Comments by Dr Rifkin and Dr Dawdy. 2008 , 28, 368	
243	Olanzapine-associated new-onset atrial fibrillation. 2008 , 28, 354-5	8
242	Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up. 2008 , 28, 363-7	57
241	Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study. 2008 , 28, 348-9	9
240	A comparison of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in DBA/2 and C57BL/6 inbred mice. 2008 , 19, 530-42	10
239	Citalopram-associated spontaneous ejaculations. 2008 , 28, 360-1	6

238	Galantamine as an adjunctive treatment in major depression. 2008 , 28, 357-9	18
237	Aripiprazole-induced parkinsonism and its association with dopamine and serotonin receptor polymorphisms. 2008 , 28, 352-3	4
236	Aripiprazole and haloperidol: beneficial combination antipsychotic therapy for a schizophrenic patient. 2008 , 31, 173-5	4
235	Management of psychosis in patients with Alzheimer's disease: focus on aripiprazole. 2008 , 3, 491-501	10
234	Treatment and prevention of mania in bipolar I disorder: focus on aripiprazole. 2009 , 5, 279-88	6
233	A UK consensus on the administration of aripiprazole for the treatment of mania. 2009 , 23, 231-40	18
232	Effectiveness Study of Venlafaxine-XR Combined with Aripiprazole for Chronic or Recurrent Major Depressive Disorder. 2009 , 43, 956-967	8
231	Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects. 2009 , 12, 941-52	43
230	A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. 2009 , 24, 145-52	13
229	Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. 2009 , 202, 315-28	122
228	Repeated aripiprazole administration attenuates cocaine seeking in a rat model of relapse. 2009 , 207, 401-11	30
227	Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review. 2009 , 8, 16	29
226	Aripiprazole in combination with other antipsychotic drugs may worsen psychosis. 2009 , 34, 245-6	18
225	Development of an LC-MS/MS method for the simultaneous quantification of aripiprazole and dehydroaripiprazole in human plasma. 2009 , 385, 270-7	32
224	The effects of antipsychotic drugs administration on 5-HT1A receptor expression in the limbic system of the rat brain. 2009 , 164, 1754-63	25
223	Decreased density of serotonin 2A receptors in the superior temporal gyrus in schizophrenia--a postmortem study. 2009 , 33, 867-71	33
222	A review of the safety and tolerability of aripiprazole. 2009 , 8, 373-86	34
221	Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia. 2009 , 50, 317-24	36

220	Prolonged toxicity in a 2-year-old after accidental ingestion of aripiprazole. 2009 , 25, 105-6	9
219	What is the mechanism for aripiprazole's effect on reducing olanzapine-associated obesity?. 2010 , 30, 480-1	7
218	Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex. 2010 , 16, 502-15	57
217	Atypical antipsychotic metabolism and excretion. 2010 , 11, 516-25	61
216	The effect of aripiprazole on cue-induced brain activation and drinking parameters in alcoholics. 2010 , 30, 365-72	56
215	Integration of Label-Free Detection Methods in GPCR Drug Discovery. 2010 , 252-275	4
214	Superior mesenteric artery syndrome: a rare etiology of upper intestinal obstruction in adults. 2010 , 34, 403-6	9
213	The effect of dopamine partial agonists on the nicotine dependency in patients with schizophrenia. 2010 , 25, 187-90	21
212	D2 receptor occupancy in conscious rat brain is not significantly distinguished with [3H]-MNPA, [3H]-(+)-PHNO, and [3H]-raclopride. 2010 , 64, 624-33	14
211	Thermal stability of aripiprazole monohydrate investigated by Raman spectroscopy. 2010 , 54, 169-173	10
210	Effectiveness of aripiprazole in a patient with presumed idiopathic Parkinson's disease and chronic paranoid schizophrenia. 2010 , 64, 108-9	6
209	Bucuk ve Genlerde Aripiprazol Kullanım Olgu Serisi. 2010 , 20, 84-93	3
208	Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole. 2010 , 6, 47-58	27
207	Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. 2010 , 24, 1019-29	42
206	The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder. 2010 , 24, 537-46	17
205	Dissociable control of impulsivity in rats by dopamine d2/3 receptors in the core and shell subregions of the nucleus accumbens. 2010 , 35, 560-9	101
204	Antipsicotici atipici nel trattamento farmacologico del disturbo borderline di personalit�una revisione sistematica. 2010 , 29, 51-58	
203	Potential control of antipsychotic-induced hyperprolactinemia and obesity in children and adolescents by aripiprazole. 2010 , 34, 1157-8; author reply 1159	5

202	Abstracts of the 2010 Meeting of the International Neuro-Ophthalmology Society, Lyon, France. 2010 , 34, 131-288	2
201	Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. 2011 , 25, 109-27	62
200	Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment. 2011 , 11, 1541-52	12
199	Repetitive administration of aripiprazole enhances locomotor response to methamphetamine in mice. 2011 , 216, 621-5	1
198	Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. 2011 , 59, 925-35	95
197	Sudden unexpected death in epilepsy associated with progressive deterioration in heart rate variability. 2011 , 21, 103-5	24
196	Psychosis associated with switching from risperidone to aripiprazole in an adolescent on methylphenidate treatment. 2011 , 35, 648-9	7
195	Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence. 2011 , 7, 319-23	13
194	Impulse control loss rapidly reversed by aripiprazole in a patient with concomitant bipolar disease type I and posttraumatic frontal lobe lesions. 2011 , 2011,	1
193	Aripiprazole-associated leukopenia with coadministration of fluoxetine: a case report. 2011 , 31, 376-7	5
192	Potential control of risperidone-related cognitive deficits by adjunctive aripiprazole treatment. 2011 , 31, 135-6; author reply 136-7	1
191	Reply to Comments by Dr Ishitobi et al. 2011 , 31, 401	1
190	Schizophrenia: a systematic review of the disease state, current therapeutics and their molecular mechanisms of action. 2011 , 18, 1380-404	20
189	Gilles de la Tourette syndrome: the complexities of phenotype and treatment. 2011 , 72, 100-7	65
188	[Aripiprazole use in children and adolescent psychiatric patients]. 2011 , 66, 123-30	2
187	Attenuation of reinforcing and psychomotor stimulant effects of amphetamine by aripiprazole. 2011 , 16, 55-63	7
186	Effectiveness of aripiprazole for medication overuse headache: a case report. 2011 , 65, 296-8	1
185	An open trial of aripiprazole for the treatment of delirium in hospitalized cancer patients. 2011 , 9, 351-7	40

184	Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders. 2011 , 20, 127-35	27
183	Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex. 2011 , 214, 639-52	48
182	Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study. 2011 , 28, 341-8	16
181	Aripiprazole in anorexia nervosa and low-weight bulimia nervosa: case reports. 2011 , 44, 269-75	37
180	Aripiprazole for the treatment of irritability associated with autism. 2011 , 12, 635-40	33
179	Aripiprazole for the treatment of bipolar disorder: a review of current evidence. 2011 , 12, 473-88	7
178	Add-on treatment of aripiprazole in an adult onychophagia patient. 2012 , 3,	
177	Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol. 2012 , 32, 778-86	5
176	Effects of amisulpride and aripiprazole on progressive-ratio schedule performance: comparison with clozapine and haloperidol. 2012 , 26, 1231-43	6
175	Neurite outgrowth mediated by the heat shock protein Hsp90 α a novel target for the antipsychotic drug aripiprazole. 2012 , 2, e170	27
174	Unexpected effect of aripiprazole on nociceptive pain. 2012 , 2, 211-2	10
173	No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol: a double-blind placebo-controlled trial. 2012 , 27, 114-20	10
172	Recent Approaches to the Synthesis of Aripiprazole [A New Generation Antipsychotic Drug]. 2012 , 9, 374-380	2
171	Safety, Efficacy, and Patient Acceptability of Aripiprazole in the Maintenance Treatment of Bipolar Disorder. 2012 , 4, CMT.S7388	
170	Effect of aripiprazole on anxiety associated with ethanol physical dependence and on ethanol-induced place preference. 2012 , 118, 215-24	15
169	P.5.e.004 Treatment of Alzheimer's disease: which effects on caregivers do we find?. 2012 , 22, S388-S389	
168	P.6.a.001 Augmentation therapy of aripiprazole with escitalopram in patients with co-occurrence of depression and alcohol dependence. 2012 , 22, S389	1
167	Development and validation of an LC-ESI-MS method for quantitative determination of aripiprazole in human plasma and an application to pharmacokinetic study. 2012 , 50, 893-901	15

166	Adsorptive stripping voltammetric methods for determination of aripiprazole. 2012 , 2, 193-199	14
165	Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). 2012 , 29, 850-4	60
164	Treatment of cerebellar cognitive affective syndrome with aripiprazole. 2012 , 5, 233-8	7
163	Determination of aripiprazole in rat plasma and brain using ultra-performance liquid chromatography/electrospray ionization tandem mass spectrometry. 2012 , 26, 1325-32	21
162	Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature. 2012 , 37, 370-2	16
161	Evidence review and clinical guidance for the use of ziprasidone in Canada. 2013 , 12, 1	5
160	A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder. 2013 , 228, 175-85	25
159	Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. 2013 , 13, 851-70	65
158	Atypical antipsychotics in the treatment of depressive and psychotic symptoms in patients with chronic schizophrenia: a naturalistic study. 2013 , 2013, 423205	5
157	SPE-UPLC-MS/MS method for sensitive and rapid determination of aripiprazole in human plasma to support a bioequivalence study. 2013 , 925, 20-5	21
156	Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits. 2013 , 4, 1026-48	54
155	Clinical pharmacology of dopamine-modulating agents in Tourette's syndrome. 2013 , 112, 281-349	40
154	Effect of combination of aripiprazole with carbamazepine and fluvoxamine on liver functions in experimental animals. 2013 , 45, 121-5	13
153	Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection. 2013 , 33, 538-41	22
152	Aripiprazole-associated acute dystonia, akathisia, and parkinsonism in a patient with bipolar I disorder. 2013 , 33, 269-70	7
151	Low dosage of aripiprazole induced neuroleptic malignant syndrome after interaction with other neuroleptic drugs. 2013 , 206-208	1
150	Active-state model of a dopamine D2 receptor-Gβ complex stabilized by aripiprazole-type partial agonists. 2014 , 9, e100069	26
149	Development and validation of a rapid and sensitive LC-MS/MS method for the determination of aripiprazole in human plasma: Application to a bioequivalence study. 2014 , 26, 203-227	4

148	Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression. 2014 , 25, 567-74	56
147	The antipsychotic aripiprazole selectively prevents the stimulant and rewarding effects of morphine in mice. 2014 , 742, 139-44	13
146	Aripiprazole use in Children and Adolescents: A Public Hospital Child Psychiatry Outpatient Department's Experience. 2014 , 24, 31-38	1
145	The advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosis. 2014 , 29, 77-85	7
144	Palau'chlor: a practical and reactive chlorinating reagent. 2014 , 136, 6908-11	122
143	Functionally selective dopamine D ₂ receptor partial agonists. 2014 , 57, 4861-75	60
142	Effect of valproate on the plasma concentrations of aripiprazole in bipolar patients. 2014 , 18, 288-92	2
141	Sensitive determination of aripiprazole using chemiluminescence reaction of tris(1,10-phenanthroline)ruthenium(II) with acidic Ce(IV). 2014 , 6, 9588-9595	3
140	Drugs currently in Phase II clinical trials for cocaine addiction. 2014 , 23, 1105-22	28
139	A rapid and selective LCMS/MS method for the quantification of aripiprazole in beagle dog plasma and its application to a pharmacokinetic study. 2014 , 44, 465-472	
138	The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. 2014 , 28, 421-53	193
137	Dosing and switching of paliperidone ER in patients with schizophrenia: recommendations for clinical practice. 2014 , 13, 10	10
136	Differential response to antipsychotics in a patient with Alzheimer's disease. 2014 , 18, 10-12	
135	Different effects of bifeprunox, aripiprazole, and haloperidol on body weight gain, food and water intake, and locomotor activity in rats. 2014 , 124, 167-73	14
134	Delirium in advanced age and dementia: A prolonged refractory course of delirium and lower functional status. 2015 , 13, 1113-21	8
133	Does Combining Aripiprazole With Other Antipsychotics Worsen Psychosis?. 2015 , 35, 470-1	1
132	Pretreatment or Posttreatment with Aripiprazole Attenuates Methamphetamine-induced Stereotyped Behavior in Mice. 2015 , 9, 1-10	3
131	Exacerbation of tics after combining aripiprazole with pimozide: a case with Tourette Syndrome. 2015 , 35, 350-1	8

130	Unique Effects of Acute Aripiprazole Treatment on the Dopamine D2 Receptor Downstream cAMP-PKA and Akt-GSK3 β Signalling Pathways in Rats. 2015 , 10, e0132722	20
129	Aripiprazole adjunct treatment in bipolar I or II disorder, depressed state: a 2-year clinical study. 2015 , 203, 58-64	4
128	Synthesis and binding properties of new long-chain 4-substituted piperazine derivatives as 5-HT $_{1A}$ and 5-HT $_{2A}$ receptor ligands. 2015 , 25, 1427-30	18
127	Spectral and molecular modeling studies on the influence of β -cyclodextrin and its derivatives on aripiprazole-human serum albumin binding. 2015 , 131, 65-74	16
126	Case Reports of Aripiprazole Causing False-Positive Urine Amphetamine Drug Screens in Children. 2015 , 136, e1625-8	10
125	Treatment of clozapine-associated weight gain: a systematic review. 2015 , 71, 389-401	33
124	Graphene/TiO $_2$ /polyaniline nanocomposite based sensor for the electrochemical investigation of aripiprazole in pharmaceutical formulation. 2015 , 21, 2039-2049	12
123	Functional magnetic resonance imaging reveals abnormal brain connectivity in EGR3 gene transfected rat model of schizophrenia. 2015 , 460, 678-83	8
122	Aripiprazole may be effective as an add-on treatment in bulimic symptoms of eating disorders. 2015 , 35, 93-5	5
121	Cognitive differences in schizophrenia on long-term treatments with clozapine, risperidone and typical antipsychotics. 2015 , 30, 89-95	13
120	5-HT $_{1A}$ receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson's disease and schizophrenia. 2015 , 26, 45-58	23
119	CFBSA: a novel and practical chlorinating reagent. 2015 , 51, 14852-5	25
118	The antipsychotic aripiprazole induces antinociceptive effects: Possible role of peripheral dopamine D2 and serotonin 5-HT $_{1A}$ receptors. 2015 , 765, 300-6	17
117	New functional activity of aripiprazole revealed: Robust antagonism of D2 dopamine receptor-stimulated G β signaling. 2015 , 93, 85-91	27
116	Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: the complex mechanism of blonanserin action involving D $_{1\beta}$ -HT $_{1A}$ and D $_{1\beta}$ NMDA receptors in the mPFC. 2015 , 40, 601-13	103
115	Aripiprazole and Haloperidol Activate GSK3 β Dependent Signalling Pathway Differentially in Various Brain Regions of Rats. 2016 , 17, 459	11
114	Aripiprazole relieves catatonia but worsens hallucination in a patient with catatonic schizophrenia. 2016 , 8, 176	2
113	Design and synthesis of new homo and hetero bis-piperazinyl-1-propanone derivatives as 5-HT $_{7R}$ selective ligands over 5-HT $_{1A}$ R. 2016 , 26, 4052-6	13

112	Design and synthesis of dual 5-HT _{1A} and 5-HT ₇ receptor ligands. 2016 , 24, 3464-71	16
111	Story of an Age-Old Reagent: An Electrophilic Chlorination of Arenes and Heterocycles by 1-Chloro-1,2-benziodoxol-3-one. 2016 , 18, 1976-9	55
110	Low-Dose Aripiprazole Augmentation in Amitriptyline-Resistant Burning Mouth Syndrome: Results from Two Cases. 2017 , 18, 814-815	7
109	XMetDB: an open access database for xenobiotic metabolism. 2016 , 8, 47	5
108	2-Bromoterguride-a potential atypical antipsychotic drug without metabolic effects in rats. 2016 , 233, 3041-50	2
107	Chronic administration of aripiprazole activates GSK3 β -dependent signalling pathways, and up-regulates GABAA receptor expression and CREB1 activity in rats. 2016 , 6, 30040	18
106	Acute Unilateral Myopia Induced by Add-On Aripiprazole: A Case Report. 2016 , 26, 68-71	2
105	Comparing the Effectiveness and Safety of the Addition of and Switching to Aripiprazole for Resolving Antipsychotic-Induced Hyperprolactinemia: A Multicenter, Open-Label, Prospective Study. 2016 , 39, 288-294	19
104	An update of safety of clinically used atypical antipsychotics. 2016 , 15, 1329-47	90
103	Role of Dopamine 2 Receptor in Impaired Drug-Cue Extinction in Adolescent Rats. 2016 , 26, 2895-904	31
102	Aripiprazole Use in Children Diagnosed with Down Syndrome and Comorbid Autism Spectrum Disorders. 2016 , 26, 306-8	1
101	Aripiprazole. 2017 , 34, 180-185	16
100	Efficacy, acceptability and tolerability of 8 atypical antipsychotics in Chinese patients with acute schizophrenia: A network meta-analysis. 2017 , 185, 73-79	22
99	Aripiprazole Suppression of Drinking in a Clinical Laboratory Paradigm: Influence of Impulsivity and Self-Control. 2017 , 41, 1370-1380	14
98	Lavender Oil Preparation (Silexan) for Treating Anxiety: An Updated Meta-Analysis. 2017 , 37, 115-117	12
97	5-HT _{1A} C-1019G (rs6295) Predicts Aripiprazole Treatment Response Specifically for Cognitive and Depressive Symptoms in Schizophrenia. 2017 , 37, 114-118	2
96	A highly efficient heterogeneous copper-catalyzed chlorodeboronation of arylboronic acids leading to chlorinated arenes. 2017 , 7, 764-770	6
95	Transition-Metal-Free Decarboxylative Iodination: New Routes for Decarboxylative Oxidative Cross-Couplings. 2017 , 139, 11527-11536	81

94	Sustained remission and symptom stability in patients with schizophrenia receiving aripiprazole once-monthly: a 52-week, open-label, maintenance study. 2017 , 27, S942-S943	
93	The Place of Antipsychotics in the Therapy of Anxiety Disorders and Obsessive-Compulsive Disorders. 2017 , 19, 103	17
92	Current status of biological treatment options in Autism Spectrum Disorder. 2017 , 30, 1-10	7
91	Lurasidone for the treatment of irritability and anger in autism spectrum disorders. 2017 , 26, 985-989	11
90	Successful Treatment Response with Aripiprazole Augmentation of SSRIs in Refractory Obsessive-Compulsive Disorder in Childhood. 2017 , 48, 699-704	12
89	Antipsychotic drugs in Huntington's disease. 2017 , 17, 227-237	16
88	Demographic and pharmacological profile in hospitalized patients treated with long-acting injectable aripiprazole. 2017 , 27, S942	
87	Aripiprazole Facilitates Extinction of Conditioned Fear in Adolescent Rats. 2017 , 11, 76	18
86	Update on the Pharmacological Treatment of Tics with Dopamine-Modulating Agents. 2018 , 9, 651-672	20
85	Combined treatment with aripiprazole and antidepressants reversed some MK-801-induced schizophrenia-like symptoms in mice. 2018 , 70, 623-630	7
84	Urinary retention associated with aripiprazole: Report of a new case and review of the literature. 2018 , 73, 287-289	3
83	Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia: a 24-week follow-up study. 2018 , 33, 155-162	7
82	Overdoses with Aripiprazole: Signs, Symptoms and Outcome in 239 Exposures Reported to the Danish Poison Information Centre. 2018 , 122, 293-298	6
81	Regioselective Chlorination of Aryl C-Br bonds with Hypervalent Iodine(III) Reagent 1-Chloro-1,2-benziodoxol-3-one. 2018 , 7, 324-327	8
80	Add-on Aripiprazole for Atypical Antipsychotic-induced, Clinically Significant Hyperprolactinemia. 2018 , 40, 38-40	3
79	Early antipsychotic treatment in juvenile rats elicits long-term alterations to the adult serotonin receptors. 2018 , 14, 1569-1583	8
78	The Ambit of Phytotherapy in Psychotic Care. 2018 ,	
77	TARC: Turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel. 2018 , 8, 271-285	0

76	Prolonged QRS Widening After Aripiprazole Overdose. 2019 , 35, e209-e212	2
75	Potentiating and synergistic effect of grapefruit juice on the antioxidant and anti-inflammatory activity of aripiprazole against hydrogen peroxide induced oxidative stress in mice. 2018 , 18, 106	9
74	Aripiprazole-Induced Diurnal and Nocturnal Enuresis in Down's Syndrome. 2018 , 11, 247-250	1
73	Using antipsychotics for behavioral problems in children. 2018 , 19, 1475-1488	13
72	Clinical Pharmacokinetics of Atypical Antipsychotics: An Update. 2018 , 57, 1493-1528	57
71	Effect of sinapic acid on aripiprazole pharmacokinetics in rats: Possible food drug interaction. 2019 , 27, 332-338	6
70	Antipsychotics for Amphetamine Psychosis. A Systematic Review. 2019 , 10, 740	8
69	Aripiprazole causing false positive urine amphetamine drug screen in an adult patient with bipolar disorder. 2019 , 94, 152126	2
68	Stability Indicating Spectrophotometric and Chemometric Methods for Determination of Aripiprazole in Presence of its Degradation Products, A Comparative Study. 2019 , 9, 258-272	2
67	Selectfluor-promoted regioselective chlorination/bromination of 2-aminopyridines and 2-aminodiazines using LiCl/LiBr. 2019 , 17, 6342-6345	10
66	Blonanserin ameliorates social deficit through dopamine-D receptor antagonism in mice administered phencyclidine as an animal model of schizophrenia. 2019 , 128, 127-134	11
65	Co-treatment with antidepressants and aripiprazole reversed the MK-801-induced some negative symptoms of schizophrenia in rats. 2019 , 71, 768-773	6
64	Aripiprazole for the treatment of psychotic symptoms in patients with dementia with Lewy bodies: a case series. 2019 , 15, 543-547	6
63	Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: A systematic review and meta-analysis. 2019 , 44, 163-173	10
62	Sulfoxide-Promoted Chlorination of Indoles and Electron-Rich Arenes with Chlorine as Nucleophile. 2020 , 362, 1039-1045	3
61	Aripiprazole prevents stress-induced anxiety and social impairment, but impairs antipredatory behavior in zebrafish. 2020 , 189, 172841	5
60	Influence of EGR3 Transfection on Imaging and Behavior in Rats and Therapeutic Effect of Risperidone in Schizophrenia Model. 2020 , 11, 00787	0
59	A safety evaluation of aripiprazole in the treatment of schizophrenia. 2020 , 19, 1529-1538	10

58	Combination therapy of brexpiprazole and aripiprazole for an adolescent patient with a first episode of schizophrenia: A case report. 2020 , 74, 666-667	
57	Differential effects of different antipsychotic drugs on cognitive function in patients with chronic schizophrenia. 2020 , 35, 1-8	2
56	Pharmacogenomics and Psychopharmacology. 2020 , 151-202	2
55	Effect of combined treatment with aripiprazole and antidepressants on the MK-801-induced deficits in recognition memory in novel recognition test and on the release of monoamines in the rat frontal cortex. 2020 , 393, 112769	8
54	The Role of the Dopamine D2 Receptor in Form-Deprivation Myopia in Mice: Studies With Full and Partial D2 Receptor Agonists and Knockouts. 2020 , 61, 47	5
53	Aripiprazole for the treatment of delusional disorders: A systematic review. 2020 , 66, 34-43	3
52	Enhanced dissolution, permeation and oral bioavailability of aripiprazole mixed micelles: In vitro and in vivo evaluation. 2020 , 583, 119361	13
51	Effective Treatment of 2 Childhood Depression Cases Carrying High Risk of Bipolar Disorder With Aripiprazole Monotherapy. 2021 , 41, 223-225	
50	Regional brain network and behavioral alterations in EGR3 gene transfected rat model of schizophrenia. 2021 , 15, 2606-2615	1
49	Sex differences in the association between serum BDNF and cognitive impairment in schizophrenia patients using various antipsychotics. 2021 , 138, 492-499	1
48	Impact of repeated co-treatment with escitalopram and aripiprazole on the schizophrenia-like behaviors and BDNF mRNA expression in the adult Sprague-Dawley rats exposed to glutathione deficit during early postnatal development of the brain. 2021 , 73, 1712-1723	1
47	Olfactory Reference Syndrome (Halitophobia) With Oral Cenesthopathy Treated With Low-Dose Aripiprazole: A Case Report. 2021 , 44, 235-237	1
46	Dopamine Receptors and the Treatment of Schizophrenia. 2010 , 431-477	5
45	Introduction. 3-11	4
44	[Aripiprazole - a medical treatment alternative for Tourette Syndrome in childhood and adolescence]. 2010 , 38, 291-8	1
43	Understanding variability in the pharmacokinetics of atypical antipsychotics - focus on clozapine, olanzapine and aripiprazole population models. 2020 , 52, 1-18	10
42	Incontinence and mood disorder: is there an association?. 2010 , 2010,	3
41	Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials. 2013 , 8, e70179	43

40	Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity. 2017 , 15, 1192-1207	31
39	How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?. 2020 , 11, 491895	10
38	Adipocyte Triglyceride Content and Adipogenesis in Aripiprazole Treated Rats. 2013 , 9, 251-257	1
37	Hippocampal and thalamic neuronal metabolism in a putative rat model of schizophrenia. 2013 , 8, 2415-23	3
36	Aripiprazole for the treatment of Tourette's disorder. 2005 , 7, 296-9	13
35	Aripiprazole therapy for nicotine dependence. 2006 , 8, 47-9	3
34	An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. 2006 , 8, 82-7	36
33	Aripiprazole worsens psychosis: a case report. 2006 , 8, 380-1	5
32	Aripiprazole in schizotypal personality disorder: a case report. 2008 , 10, 481-2	1
31	Validated spectrophotometric quantification of aripiprazole in pharmaceutical formulations by using multivariate technique. 2013 , 3, 469-72	7
30	Aripiprazole, A New Generation Antipsychotic: Current Research and Clinical Practice. 2021 , 16, 1-5	
29	Mecanismos de acción de los medicamentos antipsicóticos de segunda generación en la esquizofrenia: conocimientos obtenidos a partir de los estudios de imágenes cerebrales. 2005 , 12, 231-244	
28	How Antipsychotics Work: Linking Receptors to Response. 2009 , 540-557	
27	Are combination therapies with aripiprazole and other antipsychotics pharmacologically rational?. 2011 , 2, 32-33	
26	Withdrawal seizure associated with high dosage of aripiprazole and fluoxetine: a case report. 2011 , 01, 30-32	
25	Encyclopedia of Child Behavior and Development. 2011 , 2-3	
24	Hypoprolactinemia and Extrapyrimal Symptoms in Male Schizophrenia or Psychotic Affective Disorder Patients Treated with Aripiprazole. 2012 , 3, 18-22	
23	Aripiprazole long-acting injectable (ABILIFY MAINTENA) for treatment of schizophrenia. 2015 , 5, 149-161	1

22	Worsening of Psychotic Symptoms in Patients with Chronic Schizophrenia after Switching to or Combining Aripiprazole and Aripiprazole Monthly (Abilify Maintena). 2020 , 59, 166	
21	Dosaggio dell'aripiprazolo totale: messa a punto del metodo su analizzatore Cobas® 8000. 2020 , 16,	
20	Predicting pharmacokinetic stability by multiple oral administration of atypical antipsychotics. 2013 , 10, 23-30	5
19	Schizophrenia: overview and treatment options. 2014 , 39, 638-45	118
18	Comparison the effectiveness of aripiprazole and risperidone for the treatment of acute bipolar mania. 2014 , 19, 733-8	3
17	Clinical pharmacology of atypical antipsychotics: an update. 2014 , 13, 1163-91	128
16	Efficacy of Atypical Antipsychotics in the Management of Acute Agitation and Aggression in Hospitalized Patients with Schizophrenia or Bipolar Disorder: Results from a Systematic Review. 2016 , 28, 241-252	4
15	N-Acetylcysteine and Aripiprazole Improve Social Behavior and Cognition and Modulate Brain BDNF Levels in a Rat Model of Schizophrenia.. 2022 , 23,	3
14	Aripiprazole as First-Line Therapy for Late-Life Depression: A Case Note Review.. 2022 ,	
13	DataSheet_1.pdf. 2019 ,	
12	Table_1.docx. 2019 ,	
11	Dopamine Dysregulation Syndrome in Parkinson Disease and Remission After Treatment With Aripiprazole.. 2022 ,	
10	Experimental Studies Indicate That ST-2223, the Antagonist of Histamine H3 and Dopamine D2/D3 Receptors, Restores Social Deficits and Neurotransmission Dysregulation in Mouse Model of Autism. 2022 , 15, 929	
9	Novel Eco-Friendly Stability Indicating Capillary Zone Electrophoresis Method for Determination of Aripiprazole in Tablet Dosage Form: DoE Directed Optimization, Development and Method Validation. 2022 ,	
8	Concurrent measures of impulsive action and choice are partially related and differentially modulated by dopamine D1- and D2-like receptors in a rat model of impulsivity.	
7	Concurrent Measures of Impulsive Action and Choice are Partially Related and Differentially Modulated by Dopamine D1- and D2-Like Receptors in a Rat Model of Impulsivity.	0
6	Neuroprotective effects of aripiprazole in stress-induced depressive-like behavior: possible role of CACNA1C. 2022 , 102170	0
5	Recent Development of Nano-Carbon Material in Pharmaceutical Application: A Review. 2022 , 27, 7578	1

- 4 Concurrent measures of impulsive action and choice are partially related and differentially modulated by dopamine D1- and D2-like receptors in a rat model of impulsivity. **2023**, 222, 173508
- 3 Modern possibilities of anti-relapse therapy of schizophrenia (experience with the use of aripiprazole). **2022**, 122, 63
- 2 Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review.
- 1 Does partial blockade of dopamine D2 receptors with Amisulpride cause anhedonia? An experimental study in healthy volunteers. **2023**,